Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Xspray Pharma AB ( (SE:XSPRAY) ) has shared an announcement.
Xspray Pharma has resolved to carry out a rights issue of approximately SEK 83 million, with a potential SEK 20 million over-allotment, giving existing shareholders preferential rights at a 19 percent discount to the theoretical ex-rights price and backed by subscription undertakings covering about 49 percent of the issue. The capital raise is intended to finance the planned U.S. launch preparations and commercialization of lead candidates Dasynoc and XS003-nilotinib, support broader portfolio development and manufacturing upgrades, and, assuming product approvals, cover working capital needs through 2026 as the company targets a multibillion-dollar chronic myeloid leukemia and oncology market alongside expiring originator patents.
The rights issue structure grants one subscription right per share with ten rights required for one new share, and the board may allocate the over-allotment portion to strategic or qualified investors to further strengthen the shareholder base. Strong participation commitments from major owners, including institutional investors and pension funds, underscore confidence in Xspray’s strategy to use its HyNap technology to bring improved oncology drugs to market in parallel with originator and potential generic products, positioning the company for an inflection toward revenue generation if regulatory milestones are met.
The most recent analyst rating on (SE:XSPRAY) stock is a Hold with a SEK25.00 price target. To see the full list of analyst forecasts on Xspray Pharma AB stock, see the SE:XSPRAY Stock Forecast page.
More about Xspray Pharma AB
Xspray Pharma AB is a Swedish pharmaceutical company specializing in improved formulations of marketed protein kinase inhibitors for cancer treatment, using its patented HyNap platform to enhance poorly soluble crystalline drugs. Its pipeline includes product candidates such as Dasynoc, XS003-nilotinib, XS008 and XS025, targeting branded therapies like Sprycel, Tasigna, Inlyta and Cabometyx in high-value oncology markets.
Average Trading Volume: 45,657
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.09B
Find detailed analytics on XSPRAY stock on TipRanks’ Stock Analysis page.